JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge.

ISSN: Active
eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
The relationship between medical therapy and sarcopenia in advanced non-small cell lung cancer patients
Abstract
Aims: Sarcopenia, characterized by loss of skeletal muscle mass and function, is associated with worse clinical outcomes in cancer patients. Cancer treatment may influence the development of sarcopenia. On the other hand, the presence of sarcopenia before or after treatment may affect the response to cancer therapy. This vicious circle is associated with a higher mortality risk. The aim of this study was to determine the prevalence of sarcopenia in newly diagnosed advanced non-small cell lung cancer (NSCLC) patients before and after standard chemotherapy protocols and to investigate the relationship between sarcopenia and treatment response.
Methods: Between October 13, 2022, and February 13, 2023, 38 patients over 18 years of age with advanced NSCLC who were admitted to the Medical Oncology Department Outpatient Clinic were included in the study. Bioelectrical impedance analysis (BIA) and anthropometric measurements were performed in all patients. Hand squeeze strength measured with an electronic hand dynamometer was used to assess muscle strength. Muscle performance was assessed by walking speed measured on a 4-meter track. Walking speed <0.8 m/sec was considered in favor of decreased muscle performance. The diagnosis of sarcopenia was based on the criteria of the EWGSOP study group's criteria were used to diagnose sarcopenia.
Results: Before treatment, 23.7% of patients had probable sarcopenia, 10.5% had sarcopenia, and 15.8% had severe sarcopenia. Sarcopenia developed in 21.1% of patients without sarcopenia before treatment, while 21.1% of patients with possible sarcopenia developed severe sarcopenia after treatment. The ECOG performance score and saturation level worsened in patients with increased sarcopenia after treatment. Thirty percent of patients with pre-treatment sarcopenia died after treatment, and progression was detected in all of the remaining patients after treatment. In patients whose sarcopenia score did not change after treatment, there was no significant difference in BIA parameters after treatment, while vitamin D levels increased. In patients whose sarcopenia score increased after treatment, there was a significant decrease in lean weight and lean mass index, as well as a decrease in vitamin D level. Adenocarcinoma subtype, Stage 4, and platinum-based chemotherapy were associated with an increase in the post-treatment sarcopenia score.
Conclusion: The prevalence of sarcopenia in NSCLC patients is approximately 50%, and disease stage, type, and treatment regimen play an important role in the development of sarcopenia. The presence of sarcopenia before treatment may have an impact on treatment response and increase the risk of chemotherapy-related toxicity. It is also associated with a higher mortality risk.

Keywords : Lung cancer, bioelectrical impedance, advanced cancer, chemotherapy, sarcopenia

Download Article


1. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32(4):605-644. doi:10. 1016/j.ccm.2011.09.001
2. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. 2010;39(4):412-423. doi:10.1093/ageing/afq034
3. Ying L, Yao Y, Lv H, et al. IL-17A contributes to skeletal muscle atrophy in lung cancer-induced cachexia via JAK2/STAT3 pathway. Am J Physiol Cell Physiol. 2022;322(5):C814-C824. doi:10.1152/ajpcell.00463.2021
4. Sturgeon KM, Mathis KM, Rogers CJ, Schmitz KH, Waning DL. Cancer- and chemotherapy-induced musculoskeletal degradation. JBMR Plus. 2019;3(3):e10187. doi:10.1002/jbm4.10187
5. Kawaguchi Y, Hanaoka J, Ohshio Y, et al. Does sarcopenia affect postoperative short- and long-term outcomes in patients with lung cancer?-a systematic review and meta-analysis. J Thorac Dis. 2021;13(3): 1358-1369. doi:10.21037/jtd-20-3072
6. Shiroyama T, Nagatomo I, Koyama S, et al. Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: a preliminary retrospective study. Sci Rep. 2019;9(1):2447. doi:10.1038/s41598-019-39120-6
7. Wang J, Cao L, Xu S. Sarcopenia affects clinical efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients: a systematic review and meta-analysis. Int Immunopharmacol. 2020;88:106907. doi: 10.1016/j.intimp.2020.106907
8. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9(7):629-635. doi:10.1016/S1470-2045(08)70153-0
9. Janssen I, Heymsfield SB, Baumgartner RN, Ross R. Estimation of skeletal muscle mass by bioelectrical impedance analysis. J Appl Physiol (1985). 2000;89(2):465-471. doi:10.1152/jappl.2000.89.2.465
10. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(4):601. doi: 10.1093/ageing/afz046
11. Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. 2014;14(11):754-762. doi:10.1038/nrc3829
12. Collins J, Noble S, Chester J, Coles B, Byrne A. The assessment and impact of sarcopenia in lung cancer: a systematic literature review. BMJ Open. 2014;4(1):e003697. doi:10.1136/bmjopen-2013-003697
13. Porporato PE. Understanding cachexia as a cancer metabolism syndrome. Oncogenesis. 2016;5(2):e200. doi:10.1038/oncsis.2016.3
14. Sznol M. Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype? Curr Opin Investig Drugs. 2010;11(12):1340-1341.
15. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9(7):629-635. doi:10.1016/S1470-2045(08)70153-0
16. Feliciano E, Caan BJ, Prado C, et al. Prevalence of sarcopenia and predictors of body composition among women with early-stage breast cancer. American Society of Clinical Oncology. 2017.
17. Kinsey E, Ajazi E, Wang X, Johnston MAM, Crawford J. Predictors of physical and functional loss in advanced-stage lung cancer patients receiving platinum chemotherapy. J Thorac Oncol. 2018;13(9):1294-1301. doi:10.1016/j.jtho.2018.05.029
18. de van der Schueren MAE, de Smoker M, Leistra E, Kruizenga HM. The association of weight loss with one-year mortality in hospital patients, stratified by BMI and FFMI subgroups. Clin Nutr. 2018;37(5):1518-1525. doi:10.1016/j.clnu.2017.08.024
19. Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. Nat Rev Dis Primers. 2018;4:17105. doi:10.1038/nrdp.2017.105
20. Cereda E, Pedrazzoli P, Lobascio F, et al. The prognostic impact of BIA-derived fat-free mass index in patients with cancer. Clin Nutr. 2021; 40(6):3901-3907. doi:10.1016/j.clnu.2021.04.024
21. Zhang X, Zhang Q, Feng LJ, et al. The application of fat-free mass index for survival prediction in cancer patients with normal and high body-mass index. Front Nutr. 2 2021;8:714051. doi:10.3389/fnut.2021.714051
22. Prado CM, Baracos VE, McCargar LJ, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007;13(11):3264-3268. doi:10.1158/1078-0432.CCR-06-3067
23. Davis MP, Panikkar R. Sarcopenia associated with chemotherapy and targeted agents for cancer therapy. Ann Palliat Med. 2019;8(1):86-101. doi:10.21037/apm.2018.08.02
24. Jeejeebhoy KN. Malnutrition, fatigue, frailty, vulnerability, sarcopenia and cachexia: overlap of clinical features. Curr Opin Clin Nutr Metab Care. 2012;15(3):213-219. doi:10.1097/MCO.0b013e328352694f
Article available in :
Volume 3, Issue 2, 2025
Page : 32-41
https://doi.org/10.51271/JCHOR-0059
Article Information
Received : 22 May 2024
Accepted : 10 Nis 2025
Published : 08 May 2025
Corresponding Author :

Feyza Erdem Keleş: Department of Internal Medicine, Antalya City Hospital, Antalya, Turkiye

[email protected]
Citation : Erdem Keleş F, Yalçın S, Keleş AO, Erdem TE, Bozkurt Yavuz H, Ayçiçek GŞ. The relationship between medical therapy and sarcopenia in advanced non-small cell lung cancer patients. J Curr Hematol Oncol Res. 2025;3(2):32-41.

Read: 300
Download : 249
Cited: 0
_Footer